Boston-Based Invicro Further Expands Imaging Capabilities
with Acquisition of Core Clinical, Inc.
BOSTON, MA, October 26, 2017 – Invicro, LLC, a leading provider of imaging services and software for research and drug development, announced today that it has completed the acquisition of Core Clinical, Inc., a medical imaging core lab based in Bucks County, PA.
Combined with its recent acquisition of the London-based translational research group, Imanova, the addition of Core Clinical enables Invicro to further expand its capability to provide an unmatched set of software and solutions when using medical imaging in research and drug development.
“The Core Clinical acquisition complements our current capabilities and enables us to accelerate our late-phase clinical research efforts beyond neurology into all the other indications we support in discovery and early phase research, especially oncology, cardiology and musculoskeletal programs,” said Dr. Jack Hoppin, Invicro’s CEO and Co-Founder. “We are excited to welcome Core Clinical to the Invicro family, and are already working toward a smooth integration and a seamless transition. This newest offering allows us to continue to deliver innovative and market-leading solutions that solve our clients’ most challenging problems.”
“By merging Invicro’s high-tech imaging capabilities and the Core Clinical team’s expertise from supporting over 400 imaging trials, the combined organization delivers an unmatched offering that supports the research paradigm from discovery through clinical, and all the way to post marketing studies. This unique full-service approach delivers the optimal solution to overcome complex challenges in clinical research,” said Ted Gastineau, CEO of Core Clinical. As part of the transaction integration, Core Clinical co-founder Richard Gastineau will become Chief Commercial Officer for Invicro.
The addition of Core Clinical is part of Invicro’s ongoing growth strategy to realize its mission to improve therapeutic discovery and development efforts through visualizing and quantifying biological and pathological processes in order to better diagnose, characterize, prevent, treat and, ultimately, cure disease. This growth strategy was further bolstered when Konica Minolta, Inc. (“Konica Minolta”) and Invicro announced that they recently concluded an agreement whereby Konica Minolta will acquire Invicro. The acquisition of Invicro by Konica Minolta is part of Konica Minolta’s strategic development of a new platform to advance precision medicine, discover new therapeutic targets and develop new medical technologies.
Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova in 2017. Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/
About Core Clinical
Core Clinical is the next generation imaging CRO. Core focuses on being the best medical imaging core laboratory in the industry. Our 20+ years of experience allows us to develop new thinking in how we manage, analyze and deliver images and imaging data. Our advanced technology is always on, cloud based, and developed to provide speed from start up to delivery at the highest level of quality. Our efficiency allows us to be cost effective for Phase I- IV services. For more information, visit www.c2clinical.com.
For media inquiries, please contact: